vs
GOLD RESOURCE CORP（GORO）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
GOLD RESOURCE CORP的季度营收约是REGENXBIO Inc.的1.7倍（$51.3M vs $30.3M），GOLD RESOURCE CORP净利率更高（35.1% vs -221.3%，领先256.4%），GOLD RESOURCE CORP同比增速更快（295.5% vs 43.0%），GOLD RESOURCE CORP自由现金流更多（$15.3M vs $-52.8M），过去两年GOLD RESOURCE CORP的营收复合增速更高（65.6% vs 39.4%）
黄金资源公司是一家总部位于加拿大温哥华的矿业企业，目前专注于开发位于美国犹他州与内华达州交界处的金泉金银矿。公司成立于2006年，目前分别在加拿大多伦多证券交易所和美国OTCQX市场挂牌上市，核心业务聚焦贵金属矿的勘探与开发。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GORO vs RGNX — 直观对比
营收规模更大
GORO
是对方的1.7倍
$30.3M
营收增速更快
GORO
高出252.5%
43.0%
净利率更高
GORO
高出256.4%
-221.3%
自由现金流更多
GORO
多$68.1M
$-52.8M
两年增速更快
GORO
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $51.3M | $30.3M |
| 净利润 | $18.0M | $-67.1M |
| 毛利率 | 51.5% | — |
| 营业利润率 | 38.9% | -190.0% |
| 净利率 | 35.1% | -221.3% |
| 营收同比 | 295.5% | 43.0% |
| 净利润同比 | 261.6% | -31.2% |
| 每股收益（稀释后） | $0.14 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GORORGNX
| Q4 25 | $51.3M | $30.3M | ||
| Q3 25 | $24.9M | $29.7M | ||
| Q2 25 | $11.2M | $21.4M | ||
| Q1 25 | $12.4M | $89.0M | ||
| Q4 24 | $13.0M | $21.2M | ||
| Q3 24 | $13.3M | $24.2M | ||
| Q2 24 | $20.8M | $22.3M | ||
| Q1 24 | $18.7M | $15.6M |
净利润GORORGNX
| Q4 25 | $18.0M | $-67.1M | ||
| Q3 25 | $-4.7M | $-61.9M | ||
| Q2 25 | $-11.5M | $-70.9M | ||
| Q1 25 | $-8.3M | $6.1M | ||
| Q4 24 | $-11.1M | $-51.2M | ||
| Q3 24 | $-12.7M | $-59.6M | ||
| Q2 24 | $-27.0M | $-53.0M | ||
| Q1 24 | $-5.7M | $-63.3M |
毛利率GORORGNX
| Q4 25 | 51.5% | — | ||
| Q3 25 | 25.0% | — | ||
| Q2 25 | -39.4% | — | ||
| Q1 25 | -11.8% | — | ||
| Q4 24 | -46.7% | 70.2% | ||
| Q3 24 | -65.3% | 48.8% | ||
| Q2 24 | -17.3% | 52.5% | ||
| Q1 24 | -11.6% | 72.6% |
营业利润率GORORGNX
| Q4 25 | 38.9% | -190.0% | ||
| Q3 25 | -14.9% | -176.3% | ||
| Q2 25 | -102.4% | -296.3% | ||
| Q1 25 | -63.1% | 13.6% | ||
| Q4 24 | -96.9% | -242.1% | ||
| Q3 24 | -122.7% | -256.6% | ||
| Q2 24 | -52.1% | -251.3% | ||
| Q1 24 | -40.4% | -408.8% |
净利率GORORGNX
| Q4 25 | 35.1% | -221.3% | ||
| Q3 25 | -18.7% | -208.3% | ||
| Q2 25 | -102.3% | -331.8% | ||
| Q1 25 | -67.3% | 6.8% | ||
| Q4 24 | -85.9% | -241.3% | ||
| Q3 24 | -95.5% | -246.3% | ||
| Q2 24 | -129.9% | -237.7% | ||
| Q1 24 | -30.4% | -405.4% |
每股收益（稀释后）GORORGNX
| Q4 25 | $0.14 | $-1.30 | ||
| Q3 25 | $-0.03 | $-1.20 | ||
| Q2 25 | $-0.09 | $-1.38 | ||
| Q1 25 | $-0.07 | $0.12 | ||
| Q4 24 | $-0.11 | $-0.99 | ||
| Q3 24 | $-0.14 | $-1.17 | ||
| Q2 24 | $-0.30 | $-1.05 | ||
| Q1 24 | $-0.06 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $25.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $44.0M | $102.7M |
| 总资产 | $184.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GORORGNX
| Q4 25 | $25.0M | $230.1M | ||
| Q3 25 | $9.8M | $274.2M | ||
| Q2 25 | $12.7M | $323.3M | ||
| Q1 25 | $4.9M | $267.9M | ||
| Q4 24 | $1.6M | $234.7M | ||
| Q3 24 | $1.4M | $255.5M | ||
| Q2 24 | $5.3M | $290.4M | ||
| Q1 24 | $5.7M | $338.7M |
股东权益GORORGNX
| Q4 25 | $44.0M | $102.7M | ||
| Q3 25 | $26.0M | $161.5M | ||
| Q2 25 | $19.2M | $213.7M | ||
| Q1 25 | $24.6M | $274.2M | ||
| Q4 24 | $27.3M | $259.7M | ||
| Q3 24 | $37.9M | $301.4M | ||
| Q2 24 | $49.8M | $348.3M | ||
| Q1 24 | $74.9M | $390.7M |
总资产GORORGNX
| Q4 25 | $184.1M | $453.0M | ||
| Q3 25 | $164.3M | $525.2M | ||
| Q2 25 | $155.1M | $581.0M | ||
| Q1 25 | $147.7M | $490.9M | ||
| Q4 24 | $145.9M | $466.0M | ||
| Q3 24 | $154.5M | $519.1M | ||
| Q2 24 | $161.5M | $569.4M | ||
| Q1 24 | $182.8M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $24.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $15.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 29.8% | -174.0% |
| 资本支出强度资本支出/营收 | 17.3% | 1.7% |
| 现金转化率经营现金流/净利润 | 1.34× | — |
| 过去12个月自由现金流最近4个季度 | $644.0K | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GORORGNX
| Q4 25 | $24.2M | $-52.3M | ||
| Q3 25 | $-325.0K | $-56.0M | ||
| Q2 25 | $-1.3M | $-49.3M | ||
| Q1 25 | $-828.0K | $33.6M | ||
| Q4 24 | $1.3M | $-31.6M | ||
| Q3 24 | $-3.4M | $-40.5M | ||
| Q2 24 | $-63.0K | $-45.5M | ||
| Q1 24 | $1.5M | $-55.5M |
自由现金流GORORGNX
| Q4 25 | $15.3M | $-52.8M | ||
| Q3 25 | $-7.8M | $-56.5M | ||
| Q2 25 | $-3.8M | $-49.7M | ||
| Q1 25 | $-3.0M | $32.6M | ||
| Q4 24 | $58.0K | $-32.7M | ||
| Q3 24 | $-5.7M | $-40.9M | ||
| Q2 24 | $-2.1M | $-46.0M | ||
| Q1 24 | $-512.0K | $-56.0M |
自由现金流率GORORGNX
| Q4 25 | 29.8% | -174.0% | ||
| Q3 25 | -31.3% | -189.9% | ||
| Q2 25 | -34.2% | -232.8% | ||
| Q1 25 | -24.4% | 36.6% | ||
| Q4 24 | 0.4% | -154.2% | ||
| Q3 24 | -43.1% | -168.9% | ||
| Q2 24 | -10.0% | -206.2% | ||
| Q1 24 | -2.7% | -358.5% |
资本支出强度GORORGNX
| Q4 25 | 17.3% | 1.7% | ||
| Q3 25 | 30.0% | 1.7% | ||
| Q2 25 | 22.6% | 1.8% | ||
| Q1 25 | 17.7% | 1.2% | ||
| Q4 24 | 9.8% | 5.1% | ||
| Q3 24 | 17.7% | 1.3% | ||
| Q2 24 | 9.7% | 2.1% | ||
| Q1 24 | 10.7% | 3.6% |
现金转化率GORORGNX
| Q4 25 | 1.34× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GORO
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
